Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Streckel, Elisabeth ^a   Braun Reichhart, Christina ^a   Herbach, Nadja ^a   Dahlhoff, Maik ^a   Kessler, Barbara ^a   Blutke, Andreas ^a   Bähr, Andrea ^a   Übel, Nicole ^a   Eddicks, Matthias ^a   Ritzmann, Mathias ^a   Krebs, Stefan ^a   Göke, Burkhard ^a   Blum, Helmut ^a   Wanke, Rüdiger ^a   Wolf, Eckhard ^a   Renner, Simone ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adolescents; Beta cell mass; GIP receptor; GLP1 receptor agonist; Incretin based therapeutics; Liraglutide; Transgenic pig model; Type 2 diabetes

Indexed keywords

LIRAGLUTIDE; PLACEBO; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; INSULIN; TARGET OF RAPAMYCIN KINASE;

ACINAR CELL; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; FOOD INTAKE; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE TEST; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; JUVENILE ANIMAL; MIXED MEAL GLUCOSE TOLERANCE TEST; NONHUMAN; ORGAN WEIGHT; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PROTEIN PHOSPHORYLATION; STOMACH EMPTYING; TRANSGENIC PIG; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN; AGONISTS; ANIMAL; BLOOD; CELL SIZE; DISEASE MODEL; DRUG EFFECTS; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; METABOLISM; ORGAN SIZE; PATHOLOGY; PREDIABETIC STATE; SECRETION (PROCESS); SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSGENIC ANIMAL;

ACINAR CELLS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BLOOD GLUCOSE; CELL PROLIFERATION; CELL SIZE; DISEASE MODELS, ANIMAL; FEEDING BEHAVIOR; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE TOLERANCE TEST; INSULIN; LIRAGLUTIDE; MUSCLE, SKELETAL; ORGAN SIZE; PREDIABETIC STATE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; WEIGHT GAIN;

EID: 84925010827     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0431-2     Document Type: Article

References (55)

1. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262-9.
2. Assessment report for Victoza, European Medicines Agency, Doc. ref. EMEA/379172/2009, available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001026/WC500050016.pdf .
3. Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009;11 Suppl 3:26-34.
4. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39-47.
5. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet. 2013;381:117-24.
6. Flint A, Arslanian S. Treatment of type 2 diabetes in youth. Diabetes Care. 2011;34 Suppl 2:S177-83.
7. Renner S, Fehlings C, Herbach N, Hofmann A, von Waldthausen DC, Kessler B, et al. Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes. 2010;59:1228-38.
8. Takahashi H, Okamura D, Starr ME, Saito H, Evers BM. Age-dependent reduction of the PI3K regulatory subunit p85alpha suppresses pancreatic acinar cell proliferation. Aging Cell. 2012;11:305-14.
9. Gotfredsen CF, Molck AM, Thorup I, Berg Nyborg NC, Salanti Z, Knudsen LB, et al. The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates. Diabetes. 2014;63:2486-97.
10. Nyborg NC, Molck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes. 2012;61:1243-9.
11. Emamaullee JA, Merani S, Toso C, Kin T, Al-Saif F, Truong W, et al. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology. 2009;150:2145-52.
12. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab. 2002;283:E745-52.
13. Sturis J, Gotfredsen CF, Romer J, Rolin B, Ribel U, Brand CL, et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol. 2003;140:123-32.
14. Shimoda M, Kanda Y, Hamamoto S, Tawaramoto K, Hashiramoto M, Matsuki M, et al. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia. 2011;54:1098-108.
15. Larsen PJ, Wulff EM, Gotfredsen CF, Brand CL, Sturis J, Vrang N, et al. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. Diabetes Obes Metab. 2008;10:301-11.
16. Brand CL, Galsgaard ED, Tornehave D, Romer J, Gotfredsen CF, Wassermann K, et al. Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARalpha/gamma agonist on glycaemic control in Zucker diabetic fatty rats. Diabetes Obes Metab. 2009;11:795-803.
17. Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Soeborg H, et al. The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab. 2012;303:E253-64.
18. Bock T, Pakkenberg B, Buschard K. The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211. APMIS. 2003;111:1117-24.
19. Kimura T, Kaneto H, Shimoda M, Hirukawa H, Okauchi S, Kohara K, et al. Protective effects of pioglitazone and/or liraglutide on pancreatic beta-cells in db/db mice: comparison of their effects between in an early and advanced stage of diabetes. Mol Cell Endocrinol. 2015;400:78-89.
20. Butler PC, Meier JJ, Butler AE, Bhushan A. The replication of beta cells in normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab. 2007;3:758-68.
21. Menge BA, Tannapfel A, Belyaev O, Drescher R, Muller C, Uhl W, et al. Partial pancreatectomy in adult humans does not provoke beta-cell regeneration. Diabetes. 2008;57:142-9.
22. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61:1250-62.
23. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-6.
24. Nachnani JS, Bulchandani DG, Nookala A, Herndon B, Molteni A, Pandya P, et al. Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas. Diabetologia. 2010;53:153-9.
25. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595-604.
26. Wolf E, Braun-Reichhart C, Streckel E, Renner S. Genetically engineered pig models for diabetes research. Transgenic Res. 2014;23:27-38.
27. Aigner B, Renner S, Kessler B, Klymiuk N, Kurome M, Wunsch A, et al. Transgenic pigs as models for translational biomedical research. J Mol Med. 2010;88:653-64.
28. Renner S, Romisch-Margl W, Prehn C, Krebs S, Adamski J, Goke B, et al. Changing metabolic signatures of amino acids and lipids during the prediabetic period in a pig model with impaired incretin function and reduced beta-cell mass. Diabetes. 2012;61:2166-75.
29. Pacini G, Omar B, Ahren B. Methods and models for metabolic assessment in mice. J Diab Res. 2013;2013:986906.
30. Radikova Z. Assessment of insulin sensitivity/resistance in epidemiological studies. Endocr Regul. 2003;37:189-94.
31. George MM, Copeland KC. Current treatment options for type 2 diabetes mellitus in youth: today's realities and lessons from the TODAY study. Curr Diab Rep. 2013;13:72-80.
32. Batellino T, Klein D, Chatterjee DJ, Hale P, Chang CT, Arslanian S. Liraglutide trial in pediatric subjects with type 2 diabetes: safety, tolerability and pharmacokinetics/pharmacodynamics (Abstract). Diabetologia. 2012;55 Suppl 1:S7.
33. Micale SJ, Kane MP, Hogan E. Off-label use of liraglutide in the management of a pediatric patient with type 2 diabetes mellitus. Case Rep Pediatr. 2013;2013:703925.
34. Litten-Brown JC, Corson AM, Clarke L. Porcine models for the metabolic syndrome, digestive and bone disorders: a general overview. Animal. 2010;4:899-920.
35. Ribel U, Larsen MO, Rolin B, Carr RD, Wilken M, Sturis J, et al. NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. Eur J Pharmacol. 2002;451:217-25.
36. Raun K, von Voss P, Knudsen LB. Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs. Obesity. 2007;15:1710-6.
37. Jelsing J, Vrang N, Hansen G, Raun K, Tang-Christensen M, Knudsen LB. Liraglutide: short-lived effect on gastric emptying - long lasting effects on body weight. Diabetes Obes Metab. 2012;14:531-8.
38. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, Knudsen LB. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes. 2007;56:8-15.
39. Cummings BP, Stanhope KL, Graham JL, Baskin DG, Griffen SC, Nilsson C, et al. Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats. Diabetes. 2010;59:2653-61.
40. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131-57.
41. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol. 1995;32:13-6.
42. Ellenbroek JH, Tons HA, van Meeteren MJ W, de Graaf N, Hanegraaf MA, Rabelink TJ, et al. Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. Diabetologia. 2013;56:1980-6.
43. Garber AJ. Incretin effects on beta-cell function, replication, and mass: the human perspective. Diabetes Care. 2011;34 Suppl 2:S258-63.
44. Renner S, Braun-Reichhart C, Blutke A, Herbach N, Emrich D, Streckel E, et al. Permanent neonatal diabetes in INS(C94Y) transgenic pigs. Diabetes. 2013;62:1505-11.
45. Klip A, Paquet MR. Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care. 1990;13:228-43.
46. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 2011;12:21-35.
47. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013;493:338-45.
48. Carrera AC. TOR signaling in mammals. J Cell Sci. 2004;117:4615-6.
49. Bock T, Kyhnel A, Pakkenberg B, Buschard K. The postnatal growth of the beta-cell mass in pigs. J Endocrinol. 2003;179:245-52.
50. Montanya E, Nacher V, Biarnes M, Soler J. Linear correlation between beta-cell mass and body weight throughout the lifespan in Lewis rats: role of beta-cell hyperplasia and hypertrophy. Diabetes. 2000;49:1341-6.
51. Bonner-Weir S, In't Veld PA, Weir GC. Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies. Diabetes Obes Metab. 2014;16:661-6.
52. Harja E, Lord J, Skyler JS. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology. Diabetes Technol Ther. 2013;15:609-18.
53. Drucker DJ. Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes. 2013;62:3316-23.
54. Koehler JA, Baggio LL, Cao X, Abdulla T, Campbell JE, Secher T et al. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Diabetes 2014.
55. ADA/EASD/IDF Statement Concerning the Use of Incretin Therapy and Pancreatic Disease, June 28, 2013; available from: http://www.diabetes.org/newsroom/press-releases/2013/recommendations-for.html#sthash.rYN7AGwy.dpuf .